Normative Modelling of Brain Volume for Diagnostic and Prognostic Stratification in Multiple Sclerosis

Max Korbmacher[1-3]*, Ingrid Anne Lie[4], Kristin Wesnes[5], Eric Westman[6,7], Thomas Espeseth[8,9], Ole Andreas Andreassen[11,12], Lars T. Westlye[8,11,12], Stig Wergeland[1,13-14], Hanne Flinstad Harbo[4,15], Gro Owren Nygaard[4,15], Kjell-Morten Myhr[1,13], Einar August Høgestøl[4,8,15,†], Øivind Torkildsen[1,13,†]
for the Alzheimer's Disease Neuroimaging Initiative[+]

[†]These authors contributed equally to this work.

[+]Part of the data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf

Author affiliations:
[1]Neuro-SysMed, Department of Neurology, Haukeland University Hospital, Norway
[2]Mohn Medical Imaging and Visualisation centre, Department of Radiology, Haukeland University Hospital, Norway
[3]Department for Radiography, Western Norway University of Applied Sciences, Norway
[4]Department of Neurology, Oslo University Hospital, Norway
[5]Department of Neurology, St. Olav's Hospital, Trondheim University Hospital, Norway
[6]Department of Neurobiology, Care Sciences, and Society Karolinska Institutet, Sweden
[7]The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, UK.
[8]Department of Psychology, University of Oslo, Norway
[9]Faculty of Psychology, Oslo New University College, Norway
[11]Center for Precision Psychiatry, University of Oslo and Oslo University Hospital, Norway
[12]K.G. Jebsen-Centre for Neurodevelopmental disorders, University of Oslo, Norway
[13]Department of Clinical Medicine, University of Bergen, Norway
[14]Norwegian MS-Registry and Biobank, Helse Bergen, Haukeland University Hospital, Norway
[15]Institute for Clinical Medicine, University of Oslo, Norway

Correspondence to: Max Korbmacher
Jonas Lies vei 71, 5053 Bergen, Norway
max.korbmacher@helse-bergen.no

Abstract

Background. Brain atrophy is a hallmark of multiple sclerosis (MS). For clinical translatability and individual-level predictions, brain atrophy needs to be put into context of the broader population, using reference or normative models.

Methods. Reference models of MRI-derived brain volumes were established from a large healthy control (HC) multi-cohort dataset (N=63 115, 51% females). The reference models were applied to two independent MS cohorts (N=362, T_1w-scans=953, follow-up time up to 12 years) to assess deviations from the reference, defined as Z-values. We assessed the overlap of deviation profiles and their stability over time using individual-level transitions towards or out of significant reference deviation states (|Z|>1·96). A negative binomial model was used for case-control comparisons of the number of extreme deviations. Linear models were used to assess differences in Z-score deviations between MS and propensity-matched HCs, and associations with clinical scores at baseline and over time. The utilized normative BrainReference models, scripts and usage instructions are freely available.

Findings. We identified a temporally stable, brain morphometric phenotype of MS. The right and left thalami most consistently showed significantly lower-than-reference volumes in MS (25% and 26% overlap across the sample). The number of such extreme smaller-than-reference values was 2·70 in MS compared to HC (4·51 versus 1·67). Additional deviations indicated stronger disability (Expanded Disability Status Scale: β=0·22, 95% CI 0·12 to 0·32), Paced Auditory Serial Addition Test score (β=-0·27, 95% CI -0·52 to -0·02), and Fatigue Severity Score (β=0·29, 95% CI 0·05 to 0·53) at baseline, and over time with EDSS (β=0·07, 95% CI 0·02 to 0·13). We additionally provide detailed maps of reference-deviations and their associations with clinical assessments.

Interpretation. We present a heterogenous brain phenotype of MS which is associated with clinical manifestations, and particularly implicating the thalamus. The findings offer potential to aid diagnosis and prognosis of MS.

Funding. Norwegian MS-union, Research Council of Norway (#223273; #324252); the South-Eastern Norway Regional Health Authority (#2022080); and the European Union's Horizon2020 Research and Innovation Programme (#847776, #802998).

Research in context

Evidence before this study

Reference values and normative models have yet to be widely applied to neuroimaging assessments of neurological disorders such as multiple sclerosis (MS). We conducted a literature search in PubMed and Embase (Jan 1, 2000–September 12, 2025) using the terms “MRI” AND “multiple sclerosis”, with and without the keywords “normative model*” and “atrophy”, without language restrictions. While normative models have been applied in psychiatric and developmental disorders, few studies have addressed their use in neurological conditions. Existing MS research has largely focused on global atrophy and has not provided regional reference charts or established links to clinical and cognitive outcomes.

Added value of this study

We provide regionally detailed brain morphometry maps derived from a heterogeneous MS cohort spanning wide ranges of age, sex, clinical phenotype, disease duration, disability, and scanner characteristics. By leveraging normative modelling, our approach enables individualised brain phenotyping of MS in relation to a population based normative sample.

The analyses reveal clinically meaningful and spatially consistent patterns of smaller brain volumes, particularly in the thalamus and frontal cortical regions, which are linked to disability, cognitive impairment, and fatigue. Robustness across scanners, centres, and longitudinal follow-up supports the stability and generalisability of these findings to real-world MS populations.

Implications of all the available evidence

Normative modelling offers an individualised, sensitive, and interpretable approach to quantifying brain structure in MS by providing individual-specific reference values, supporting earlier detection of neurodegeneration and improved patient stratification. A consistent pattern of thalamic and fronto-parietal deviations defines a distinct morphometric profile of MS, with potential utility for early and personalised diagnosis and disease monitoring in clinical practice and clinical trials.

Introduction

Reference values are an essential part of clinical practice across medical fields. Yet, imaging-based reference values are rarely applied in neurological practice, due to variability in results and a lack of standardisation and hence comparability. Recent advances in normative modelling allow to translate such models to neuroscientific and hence neurological contexts.[1,2] Normative models serve to quantify the degree to which an individual measure deviates from the distribution of normative reference population.[1] While previous studies have established normative models for common metrics of cortical thickness and surface area[1,3,4] as well as subcortical volumes,[5] models covering both cortical and subcortical volumes still needs to be provided. Here, we develop such models and apply them to independent MS cohorts to characterize the brain morphometric phenotype of MS, which assumes that there are common brain characteristics across people with MS.

Over the past decades, MRI research in MS has progressed from a primary focus on lesion detection to the recognition of brain atrophy as a central marker of disease progression. Earlier work demonstrated that atrophy occurs across MS phenotypes and exceeds the rates observed in normal ageing,[6–8] though technical limitations restricted its application for short-term individual monitoring.[9] More recent work provided additional insights into the interplay between MS-related neurodegeneration and ageing, where deep grey matter, and particularly thalamic atrophy was related to disability accumulation.[10] Cortical atrophy, on the other hand, has been associated with cognitive decline.[7] Alongside these advances, the broader clinical role of MRI has expanded beyond diagnosis to monitoring and treatment guidance, reflecting a shift in the field from viewing MRI primarily as a diagnostic tool to using it as a window into the long-term mechanisms of neurodegeneration and ageing in MS.[11] The next step is to establish generalisable reference values, which are practically and clinically usable.

Hence, the application of normative brain models to MS has two important functions. First, the procedure can aid to test image-derived markers suggested by the literature, such as assumptions about cortical and thalamic atrophy,[6–8] as well as to explore new potential imaging markers. Secondly, normative models can indicate individual image-based norm-deviations which are not visible by standard neuroradiological assessments, making them a potentially useful clinical tool. By overlapping individual deviation profiles, one is able to appropriately define heterogeneity across people with MS and to explore the potential of grey matter structure as an early prognostic and diagnostic MS biomarker.[12] We assessed age and sex dependent norm-deviations from regional grey matter volumes across people with MS to establish a morphometric grey matter phenotype of MS. We assessed case-control differences

of norm deviations and related the deviations to relevant clinical outcomes cross-sectionally and longitudinally.

Methods

Participants

We used seven international databases to assemble a large cross-sectional HC cohort (N=62 795 after removal of missing values; for information see Supplemental Table 1), of which N=351 were used to one-on-one age-, sex-, and intracranial volume (ICV)-match a longitudinal MS dataset (N=351 with available MRI data; 82·8% females; age range 18·5–67·6 years; T1w scans=953) using propensity scores. The remaining N=62 414 HC (50·8% females, age range 6·0–90·1) were used for model training.

The MS cohort was assembled from two independent datasets collected across Norway. The first MS sample included 88 people with MS who participated in the omega-3 fatty acid in MS (OFAMS) multicentre clinical trial conducted between 2004-2008[13]. The trial entailed monthly MRI-acquisition, and clinical examination performed every 6 months over a 2-year period, followed by a single follow-up visit about 10 years after the original trial concluded. The attrition rate was low with 96.6% (85 of 88) completing the 10-year follow-up. The second MS dataset was collected at the Oslo university hospital (OUH) during clinical and study assessments since 2012 with standard follow-ups (N=302, T_1w-scans=690), with recruitment at the first assessment.[14] Both MS cohorts were clinically assessed for motor and cognitive impairments by evaluating a) disability, using the Expanded Disability Status Scale (EDSS),[15] b) cognitive function, using Z-scores of the 3 second Paced Auditory Serial Addition Test (PASAT),[16] and c) the level of fatigue, using the mean Fatigue Severity Scale (FSS) score.[17] EDSS scores were available at all MRI timepoints, however, there was systematic missingness of PASAT and FSS scores in parts of the cohort, as these assessments were not used at all recordings. All data collections and usage were approved by respective ethical review boards, and informed consent forms were obtained (see Supplemental Note 1).

Magnetic resonance imaging (MRI) and data processing

T_1-weighted MRI data were obtained using various protocols, scanners, sites, and field strengths (1·5T or 3T). An overview of the acquisition protocols and MRI sequence information can be retrieved from the original studies (HC: Supplemental Table 1, MS: Supplemental Table 2, original studies[13,14]). After lesion-filling using FSL, regional brain volumes were extracted using the longitudinal pipeline of FreeSurfer for the longitudinal data

(v7.1.1 OFAMS and v6.0.0 for Oslo data) including people with MS, and the cross-sectional FreeSurfer pipeline for cross-sectional HC data (multiple versions, see Supplemental Table 1), and then averaged across the brain regions specified in the Desikan-Killiany atlas.[18] For training data harmonisation, we applied Combat, which was originally developed for batch effects in laboratory samples[19] and recently extended to neuroimaging data.[20] To not introduce incorrect group differences through harmonizing the test data,[21] particular in the context of the small number of subjects per scanner site,[22] we did not harmonise the test data. As a quality control measure, we report results from harmonised test data in the Supplement.

Statistical analysis

An overview of the full analysis workflow is presented in Figure 1.



***Figure 1*. Simplified analysis workflow.**

First, normative models were established on a large cohort of healthy controls covering the lifespan (6·0–90·1 years of age). Second, the reference models were applied to the MS cohort to assess deviations from the norm cross-sectionally (upper right panel) and over time (lower right panel). The colour of the mannequins in the right panels represent a single individual with multiple sclerosis.

Sex-stratified cortical and subcortical regional brain volumes were extracted using the FreeSurfer implementation of the Desikan-Killiany atlas and subcortical parcellation schemes. For model training, we used multivariate fractional polynomial regression,[23] trained on regional brain volumes of a large HC cohort, comprised of seven cohorts (N=62 467, after removal of missing values). Models were trained for each sex separately, and trained for each brain region (i), where regional brain volumes were predicted from a linear effect of ICV, to account for confounding effects of head size, a fractional polynomial (p) of age (with maximum degree m=2), and an error term (u), with $b_{0\text{-}n}$ indicating the regression coefficients.

$$region_i = b_0 + b_1 ICV_i + b_2 age^p + u_i$$

The models were then used to predict the brain volumes per region in people with MS (N=362, T_1w-scans=953), as well as in propensity-score matched cross-sectional HC sample (based on ICV, sex, and age, N=351). Z-scores, representing norm deviations, were calculated from the true volumes, predicted volumes, and model error. First, we quantified the total number of regional significant deviations or extreme lower-than-reference values, defined by Z < -1·96. The number of extreme lower-than-reference values (XLTRV) per individual was then compared between people with MS and HC, using negative binominal regression to account for overdispersion. XLTRV was then associated with disease duration, EDSS, PASAT and FSS scores at baseline, using simple linear models, and longitudinally, using linear random intercept models, using the following simplified form.

$$Clinical = b_0 + b_1 XLTRV + u$$

Note that, by training subgroup specific models and including ICV in model-training, the Z-scores in test data are already sex, age, and ICV-adjusted. Second, using the same logic from above, we assessed the impact of age, EDSS, PASAT and FSS on normative deviations (Z) cross-sectionally and longitudinally.

$$Clinical = b_0 + b_1 Z_{region} + u$$

For comparability, we report normalised effect sizes, standardized regression coefficients. The significance-level was set at a conventional alpha level=0·05, and the Benjamini-

Hochberg (FDR) correction for multiple comparisons[24] was applied. MRI data were used when also data on sex and age were available. This allowed sex-specific predictions and calculation of Z-scores using the normative models. Missingness at random was addressed using multiple imputation, where appropriate. Due to missingness, least data were available for cross-sectional correlations between FSS scores and brain volumes. Here, the minimal observable effect was f^2=0·25 (corresponding to R^2=0·20, and Pearson's r=0·45), at 80% power, alpha=0·05, 3 nominator and 43 denominator degrees of freedom. For statistical analyses, R version 4.5.0 was used. To represent spatial statistics for the examined brain areas, we used the ggseg R package.[25]

Results

Descriptives

After removing missing data on MRI, sex, and age, 72 (7·76%) EDSS scores across all sessions which were missing at random were imputed, resulting in data from 953 MRI sessions from 362 people with MS. At baseline, the 351 people with MS with available MRI data and matched with HC were aged 38·6 (9·7) years, with 250 (71·2%) being females, and an average disease duration of 4.62 (6.07) years, average EDSS of 2·0 (1·2), PASAT 46·8 (9·2) and FSS of 4·72 (1·48). Additional sub-sample baseline demographics can be found in Supplemental Table 3.

Number of extreme lower-than-reference deviations from normative brain models

The largest overlap of extreme lower-than-reference deviations across people with MS could be shown bilaterally in the thalami (25% and 26%, see Supplemental Figure 1 for distributions), followed by the right superior parietal area (16%) and pericalcarine (14%; Figure 2). Multiple other regional presented extreme deviations in more than 10% of the people with MS, including the praecuneus, fusiform area, putamen, inferior parietal area, posterior cingulate, putamen, hippocampus and parahippocampal area. These regions also presented the strongest deviations, measured by Z-scores (Supplemental Figure 1). In contrast, brain volumes among HC corresponded to reference levels (Supplemental Figure 2).



***Figure 2*. Overlap of significant deviations indicating lower brain volumes (Z<-1.96) across people with multiple sclerosis at baseline.**
Darker colours indicate a higher percentage of people with MS overlapping in deviations in the respective brain region.

Note that these deviations remained stable, indicated by maintaining the state of extreme or non-extreme deviations over time and across regions. Most people with MS (Mean 94·81% (SD 3·16%) presented no change in the total number of extreme deviations, 2·96% (SD 1·47%) of the sample presented worsening compared to the norm: the transition towards lower-than-reference brain volumes, and 2·39% (SD 1·67%) presented improvements, indicated by transitions from extreme lower-than-reference values towards non-extreme or extremely positive deviations.
At baseline, extreme lower-than-reference brain volumes indicated higher EDSS (β=0·22, 95% CI 0·12 to 0·32, p=0·0002), PASAT (β=-0·27, 95% CI -0·52 to -0·02, p=0·035), and FSS (β=0·29, 95% CI 0·05 to 0·53, p=0·021), but not disease duration (p=0·64).
Over time, the number of deviations increased with disease duration (β=0.10, 95% CI 0·04 to 0·17, p=0·002), and EDSS (β=0·07, 95% CI 0·02 to 0·13, p = 0·016), but was not associated with PASAT (p=0·271), and FSS (p=0·14).
Group-level cross-sectional case-controls comparisons presented that people with MS had nearly three times the number of norm-deviations (4·51, SE 4·95) compared to HC (1·67, SE 2·67), indicated by an incidence rate ratio of 2·70, 95% CI 2·21 to 3·30, p < 0·00001, and lower Z-scores than HC (average of regional mean absolute ΔZ=-0·22 (SE 0·48), d=-0·48, 95% CI -0·17 to 0·79, p=0·003). The regions with the largest negative Z-scores across people with MS, indicating smaller brain volumes, were the thalami (Z_{left}=-1·16, Z_{right}=-0·84), precuneus (Z_{left}=-0·94, Z_{right}=-0·94), posterior cingulate (Z_{left}=-0·91, Z_{right}=-0·70), and putamen (Z_{left}=-0·87, Z_{right}=-0·16).

Magnitude of norm-deviations and clinical associations
At baseline, multiple regional deviations were significantly associated with age, EDSS, PASAT and FSS (Figure 3). The strongest associations between smaller-than-reference volumes, disease duration and clinical outcomes encompassed an association between age in the thalamus and disease duration (left: $\beta_{duration}$=–0·37 95% CI –0·46 to –0·27; p_{FDR}<0·00001; right: $\beta_{duration}$=–0·44 95% CI –0·54 to –0·35; p_{FDR}<0·00001), and EDSS (left: β_{EDSS}=–0·26 95% CI –0·36 to –0·15; p_{FDR}=0·011; right: β_{EDSS}=–0·27 95% CI –0·37 to –0·17;

p_{FDR}=0·001). The strongest correlation for PASAT was found for the putamen (left: β_{PASAT}=0·38 95% CI 0·14 to 0·62; p_{FDR}=0·003; right: β_{PASAT}=0·30 95% CI 0·05 to 0·54; p_{FDR}=0·032). FSS was strongest associated with smaller-than-reference superior frontal lobes (left: β_{FSS}=–0·42 95% CI –0·66 to –0·19; p_{FDR}=0·002; right: β_{FSS}=–0·59 95% CI –0·80 to –0·37; p_{FDR}<0·0001).



***Figure 3*. Baseline associations of age, EDSS, PASAT, and FSS on regional Z-scores**. Std.Coeff.=standardized coefficient, EDSS= Expanded Disability Status Scale, PASAT= Paced Auditory Serial Addition Test, FSS=Fatigue Severity Scale.

Age and EDSS scores were available for N=214. Of these, only N=94 complete cases were available for PASAT and FSS scores. Considering the high level of missingness, imputation was not executed. Darker red colour indicates positive and darker blue colour negative deviations from the norm, representing larger and smaller brain volumes compared to the reference. White indicates effects equal zero. Grey indicates uncorrected p>0.05.

In longitudinal analyses, decreasing Z-values, indicated increasingly lower-than-reference brain volumes, strongly affecting superior and subcortical areas (Figure 4). This is highlighted by associations with disease duration, which were strongest in the thalami (left: $\beta_{duration}$=–0·30 95% CI –0·35 to –0·25; p_{FDR}<0·00001; right: $\beta_{duration}$=–0·27 95% CI –0·32 to –0·22; p_{FDR}<0·00001). Similarly, volumetric deviations in various cortical and subcortical regions were indicative of increasing disability (EDSS), with the strongest associations found for the thalami (left: β_{EDSS}=–0·16 95% CI –0·21 to –0·11; p_{FDR}<0·00001; right: β_{EDSS}=–0·14 95% CI –0·20 to –0·09; p_{FDR}<0·00001).

Increasing normative deviation in superior cortical areas were most indicative of worsened processing speed (PASAT, strongest association with right medial orbitofrontal cortex: β_{PASAT}=–0·24 95% CI –0·32 to –0·17; p_{FDR}<0·00001) and increasing fatigue (FSS, strongest association with the precentral area: β_{FSS}=–0·18 95% CI –0·30 to –0·06; p_{FDR}<0·00001).

The results remained unchanged when applying a harmonisation strategy directly to the test data, yet with less significant regional volume associations in cross-sectional data, and some of the ageing effects reversed (Supplemental Figure 3-6).



***Figure 4*. Longitudinal association of age, EDSS, PASAT, and FSS with regional Z-scores**

Std.Coeff.=standardized coefficient, EDSS= Expanded Disability Status Scale, PASAT= Paced Auditory Serial Addition Test, FSS=Fatigue Severity Scale.

Age and EDSS were available for 953 sessions (N=362). PASAT and FSS scores were only available for N=110 (395 sessions), being N=61 and 295 sessions in OFAMS and N=59 and 100 sessions in OUH, with this high level of missingness not allowing for imputation. Darker red colour indicates positive and darker blue colour negative deviations from the norm, representing larger and smaller brain volumes compared to the reference. White indicates effects equal zero. Grey present regions which were not assessed. All associations were significant before FDR-corrections.

Discussion

By applying normative models, trained on over 62 000 healthy individuals, to an MS cohort with several longitudinal follow-ups, we presented that extreme brain volume deviations are heterogeneously distributed across the brain. The thalamus was the region with the largest overlap of extreme deviation across patients. Around one fourth of the examined MS cohort presented extremely lower-than-reference thalamic volumes, suggesting the thalamus as the most representative region characterising MS. Note however, that the pattern of deviations from reference values was also highly heterogeneous. This regional pattern of reduced brain volume compared to the healthy population norm associated with disability, cognitive dysfunction and fatigue, which are all key symptoms of MS.

These findings align with previous literature implicating thalamic and deep grey matter atrophy in MS pathophysiology, progression and the same clinical outcomes as presented here.[6–8] However, by expressing these deviations as age- and sex-adjusted Z-scores relative to normative reference distributions, we provide interpretable, individual-level metrics.[1]

On the group level, the extent of regional norm-deviations, indicating lower brain volumes, rather than the number of affected brain areas, more consistently explained variance in clinical measures. Subcortical deviations, particularly in the thalami and the right putamen, were significantly associated with physical disability, while frontal cortical regions were associated with cognitive function and fatigue. While correlations between thalamic characteristics and clinical assessments of disability are known, the frontal cortex associations with cognitive function and fatigue are sparsely reported. However, the presented results reinforce the neuroanatomical specificity of MS symptomatology.[6–8] That

way, norm-deviations can be used to stratify patients based on an expectable phenotype, where conventional radiological markers do not appear diagnostic or prognostically useful. Moreover, norm-deviations, either quantified as Z values or total counts of extreme deviations provide stronger associations with clinical outcomes and a clearer morphometric profile than simple volumetric assessments.[26]

Our findings extend previous work on grey matter atrophy in MS by placing individual-level morphometric variation in a normative context. Compared to age- and sex-matched HC, people with MS had more than four times the number of significant deviations in brain volumes, and these deviations persisted over time. The stability of deviations per brain region across time and individuals, especially in subcortical structures, suggests a general MS-specific brain morphometric phenotype. This is the first time such phenotype has been established, which might bear potential for early diagnosis, disease monitoring and future clinical trial outcomes. Deviations from reference values can serve to assess the risk of the development of MS from radiologically isolated syndrome, from MRI examinations in general, or be a marker for progression independent of relapse activity.

Furthermore, longitudinal associations showed that the time since baseline was linked to growing divergence from the norm, suggesting that normative models could also help disentangle MS- and age-related atrophy. A proposed disease-specific process might be that the thalamus, as a relay station of major white matter tracts, loses volume as axons degenerate. Frontal degeneration might indicate another biological process, for example, accelerated atrophy compared to non-pathological agers due to increased neuroinflammation. Notably, we observed minimal changes in deviation status (from significant to non-significant or vice versa) over time, reinforcing the temporal robustness of these markers. Still, in every tenth case, transitions in the deviation status were recorded in the thalami, highlighting the importance of repeated assessments in tracking disease progression.

Normative modelling offers several advantages over conventional group-level analyses. It provides information for single individuals, allowing identification of subclinical deviations invisible to visual inspection or group averaging.[27] This is particularly relevant in MS, where early and accurate detection of grey matter atrophy could facilitate timely therapeutic adjustments.[27,28] Moreover, the integration of normative deviations into clinical workflows could complement conventional measures such as lesion load and global brain volume metrics. By enabling a regionally resolved and person-specific assessment of neurodegeneration, normative modelling could support future precision medicine approaches in MS.

These findings also open avenues to better understand cases with diagnostic challenges, and for understanding the heterogeneity of disease trajectories. Similar to previously reported deviation patterns in psychiatric disorders,[29,30] we found extensive heterogeneity across people with MS, yet with larger region-specific overlaps than in psychiatric disorders, especially in the thalamus. This underscores the potential of brain imaging assessments in MS and their further epidemiological investigation.

This study has several strengths, including the use of large, multi-site normative data, harmonised processing pipelines, robustness checks and independent longitudinal MS samples. Nonetheless, some limitations have to be noted. First, the test data presented in the main manuscript used for normative comparisons were not harmonised, which may introduce site-specific noise. On the other hand, this choice increases ecological validity and clinical applicability, and the results were stable also when computationally harmonising the data prior to analyses. Second, clinical data (particularly PASAT and FSS) were sparsely available and missing at random, limiting the statistical power for some analyses and precluding imputation. Future studies with complete longitudinal assessments of cognitive and fatigue are needed to validate and extend these findings. Additionally, while we used validated segmentation pipelines, volume estimates may be affected by scanner and MRI protocol variability, particularly in longitudinal settings. Still, our sensitivity analyses using harmonised data produced similar trends, reinforcing the robustness of the primary findings. Future studies might consider additional segmentations of thalamic subfields or the medulla to further explore MS disability associated regions with population reference values.

Our findings indicate that normative modelling could be a valuable tool for understanding MS. By measuring how an individual's brain structure deviates from a healthy reference, we observed a consistent pattern linked to clinical symptoms. On the group level, deviations in the thalamus and frontal lobe appear to be significant imaging markers associated with disability, fatigue, and processing speed. While these volumetric deviations correlate with clinical status, more research is needed to confirm their value for diagnosis or prognosis. Nevertheless, these results suggest that integrating normative modelling into MS neuroimaging pipelines could support the early detection and monitoring of neurodegeneration.

Open Data and Materials

Summary statistics and utilized code can be found in the GitHub repository: https://github.com/MaxKorbmacher/NormativeModelsMS. Multiple of the utilized dataset are sensitive, require IRB approval for usage, and can therefore not be openly shared.

Acknowledgments

We extend our sincere gratitude to the people with MS who participated in this study, whose contributions are invaluable. This research originated from different research efforts: one national intervention study (OFAMS) and ten years follow-up examinations, as well the ongoing data collections at the MS research group at the Oslo University Hospital.
We thank the OFAMS study group at numerous hospitals across Norway, as well as the group of clinicians and researchers at the Oslo University Hospital.
Finally, we want to extend our gratitude to the thousands of scanned participants in the UK Biobank study and the other utilized cohorts as well as facilitators who made this study possible by providing invaluable data to the research community.

Funding

This project was funded by the Norwegian MS Society. Analyses on the UK Biobank were performed on the Service for Sensitive Data (TSD) platform, at the University of Oslo, operated and developed by the TSD service group at the University of Oslo IT-Department (USIT). Computations were performed using resources provided by UNINETT Sigma2 (#NS9666S) – the National Infrastructure for High Performance Computing and Data Storage in Norway, supported by the Norwegian Research Council (#223273).

Part of the data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson

Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

Another part of data collection and sharing for this project was provided by the **Human Connectome Project** (HCP; Principal Investigators: Bruce Rosen, M.D., Ph.D., Arthur W. Toga, Ph.D., Van J. Weeden, MD). HCP funding was provided by the National Institute of Dental and Craniofacial Research (NIDCR), the National Institute of Mental Health (NIMH), and the National Institute of Neurological Disorders and Stroke (NINDS). HCP data are disseminated by the Laboratory of Neuro Imaging at the University of Southern California.

Declaration of interests

OAA has received a speaker's honorarium from Lundbeck, Janssen, Otsuka and Lilly, and is a consultant to Coretechs.ai and Precision Health.
LTW is a minor shareholder of baba.vision.
KMM has served on scientific advisory board for Alexion, received speaker honoraria from Biogen, Lundbeck, Novartis and Roche, and has participated in clinical trials organized by Biogen, Merck, Novartis, Otivio, Roche and Sanofi.
EAH received honoraria for advisory board activity from Sanofi-Genzyme, and his department has received honoraria for lecturing from Biogen and Merck.
ØT received speaker honoraria from and served on scientific advisory boards of Biogen, Sanofi-Aventis, Merck, and Novartis, and has participated in clinical trials organized by Merck, Novartis, Roche and Sanofi.
SW received speaker honoraria from Biogen, Sanofi-Aventis, and Janssen, and has participated in commissioned research projects funded by Merck, Novartis, and EMD Serono.
The remaining authors declare no other competing interests.

Contributions (CRediT)

MK: Conceptualisation, Data curation, Formal analysis, Investigation, Methodology, Project administration, Software, Visualization, Writing – original draft

IAL: Data curation, Writing – review & editing

KW: Writing – review & editing

EW: Writing – review & editing

TW: Writing – review & editing

OAA: Funding Acquisition, Resources, Writing – review & editing

LTW: Funding Acquisition, Resources, Writing – review & editing

SW: Writing – review & editing

HFH: Funding Acquisition, Resources, Writing – review & editing

GON: Writing – review & editing

KMM: Resources, Writing – review & editing

EAH: Funding Acquisition, Supervision, Writing – review & editing

ØT: Funding Acquisition, Resources, Supervision, Writing – review & editing

References

1. Ge, R. *et al.* Normative modelling of brain morphometry across the lifespan with CentileBrain: algorithm benchmarking and model optimisation. *Lancet Digit. Health* **6**, e211–e221 (2024).
2. Korbmacher, M. *et al.* Brain asymmetries from mid-to late life and hemispheric brain age. *Nat. Commun.* **15**, 956 (2024).
3. Bethlehem, R. A. *et al.* Brain charts for the human lifespan. *Nat* **604**, 525–533 (2022).
4. Frangou, S. *et al.* Cortical thickness across the lifespan: Data from 17,075 healthy individuals aged 3–90 years. *Hum. Brain Mapp.* **43**, 431–451 (2022).
5. Dima, D. *et al.* Subcortical volumes across the lifespan: Data from 18,605 healthy individuals aged 3–90 years. *Hum. Brain Mapp.* **43**, 452–469 (2022).
6. Eshaghi, A. *et al.* Progression of regional grey matter atrophy in multiple sclerosis. *Brain* **141**, 1665–1677 (2018).
7. Eijlers, A. J. C. *et al.* Cortical atrophy accelerates as cognitive decline worsens in multiple sclerosis. *Neurology* **93**, e1348–e1359 (2019).
8. Meijboom, R. *et al.* Patterns of brain atrophy in recently-diagnosed relapsing-remitting multiple sclerosis. *PLOS ONE* **18**, e0288967 (2023).
9. Rocca, M. A. *et al.* Brain MRI atrophy quantification in MS. *Neurology* **88**, 403–413 (2017).
10. Filippi, M. *et al.* The ageing central nervous system in multiple sclerosis: the imaging perspective. *Brain* **147**, 3665–3680 (2024).
11. Jakimovski, D. *et al.* Multiple sclerosis. *The Lancet* **403**, 183–202 (2024).
12. Stankoff, B. & Louapre, C. Can we use regional grey matter atrophy sequence to stage neurodegeneration in multiple sclerosis? *Brain* **141**, 1580–1583 (2018).

13. Torkildsen, O. *et al.* ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial. *Arch. Neurol.* **69**, 1044–1051 (2012).

14. Høgestøl, E. A. *et al.* Cross-Sectional and Longitudinal MRI Brain Scans Reveal Accelerated Brain Aging in Multiple Sclerosis. *Front. Neurol.* **10**, 450 (2019).

15. Kurtzke, J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). *Neurology* **33**, 1444–1452 (1983).

16. Merskey, H. The Psychological Effects of Concussion. By D. M. A. Gronwall and H. Sampson. Auckland University Press/Oxford University Press. 1974. Pp 118. Paperback. Price £2.50. *Br. J. Psychiatry* **128**, 501–502 (1976).

17. Krupp, L. B., LaRocca, N. G., Muir-Nash, J. & Steinberg, A. D. The Fatigue Severity Scale: Application to Patients With Multiple Sclerosis and Systemic Lupus Erythematosus. *Arch. Neurol.* **46**, 1121–1123 (1989).

18. Desikan, R. S. *et al.* An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. *NeuroImage* **31**, 968–980 (2006).

19. Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. *Biostatistics* **8**, 118–127 (2007).

20. Radua, J. *et al.* Increased power by harmonizing structural MRI site differences with the ComBat batch adjustment method in ENIGMA. *NeuroImage* **218**, 116956 (2020).

21. Nygaard, V., Rødland, E. A. & Hovig, E. Methods that remove batch effects while retaining group differences may lead to exaggerated confidence in downstream analyses. *Biostatistics* **17**, 29–39 (2016).

22. Zindler, T., Frieling, H., Neyazi, A., Bleich, S. & Friedel, E. Simulating ComBat: how batch correction can lead to the systematic introduction of false positive results in DNA methylation microarray studies. *BMC Bioinformatics* **21**, 271 (2020).

23. Royston, P. & Altman, D. G. Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling. *J. R. Stat. Soc. Ser. C Appl. Stat.* **43**, 429–453 (1994).

24. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *J. R. Stat. Soc. Ser. B Methodol.* **57**, 289–300 (1995).

25. Mowinckel, A. M. & Vidal-Piñeiro, D. Visualization of Brain Statistics With R Packages ggseg and ggseg3d. *Adv. Methods Pract. Psychol. Sci.* **3**, 466–483 (2020).

26. Korbmacher, M. *et al.* Accelerated grey matter degeneration in relapsing remitting multiple sclerosis. *MedRxiv Prepr. Serv. Health Sci.* 2025.07.01.25330635 (2025) doi:10.1101/2025.07.01.25330635.

27. Rocca, M. A. *et al.* Current and future role of MRI in the diagnosis and prognosis of multiple sclerosis. *Lancet Reg. Health – Eur.* **44**, (2024).

28. Portaccio, E. *et al.* Multiple sclerosis: emerging epidemiological trends and redefining the clinical course. *Lancet Reg. Health – Eur.* **44**, (2024).

29. Wolfers, T. *et al.* Mapping the Heterogeneous Phenotype of Schizophrenia and Bipolar Disorder Using Normative Models. *JAMA Psychiatry* **75**, 1146–1155 (2018).

30. ENIGMA Clinical High Risk for Psychosis Working Group. Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis. *JAMA Psychiatry* **81**, 77–88 (2024).